Company news
Shenzhen Chipscreen Biosciences Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Proposal from the Chairman for Share Repurchase
October 29, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Report for Q3 2026
October 27, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Signing of Project Cooperative Development Agreement and Related Party Transactions
October 21, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 20, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for NW001
October 16, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS23546 Tablets
October 14, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for CS43158 Tablets
October 12, 2026
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
October 8, 2026
Announcement on Listing and Trading of Restricted Shares from 2024 Private Placement of Shares
August 25, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 19, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 12, 2026
Announcement on Voluntary Disclosure Regarding Acceptance of Clinical Trial Application for NW001
August 5, 2026
Announcement on Adjustment of Related Matters for the 2026 Restricted Share Incentive Plan
August 4, 2026
Self-inspection Report on Trading in the Company's Shares by Insiders with Access to Inside Information in Relation to the 2026 Restricted Share Incentive Plan
July 31, 2026
Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS43158 Tablets
July 30, 2026
Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
July 26, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
July 16, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
July 15, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
July 1, 2026
Announcement on Follow-up Credit Rating Results of "Chipscreen Convertible Bonds"
June 26, 2026
Announcement on Progress in Repurchasing Shares
June 1, 2026
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple
May 22, 2026
Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
May 18, 2026
Shareholders' Inquiry Transfer Plan
May 15, 2026
Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SAR
May 14, 2026
Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property Administration
May 8, 2026
Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion Suspension
May 7, 2026
Announcement on Convening the Q1 2026 Performance Briefing
April 30, 2026
Report for Q1 2026
April 29, 2026
Indicative Announcement on the Adjustment of Convertible Bond Conversion Prices and Continuous Suspension for Convertible Shares during the Implementation of 2025 Annual Dividend Distribution
April 28, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 20, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 1, 2026
Announcement on Resolutions of the 25th Meeting of the 3rd Board of Directors
March 30, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets
March 16, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of CS08399 Tablets
March 13, 2026
Announcement on Initially Repurchasing the Company's Shares through Call Auction
March 11, 2026
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
March 10, 2026
Announcement on Adjustment of the Conversion Price and Trading Suspension/Resumption of "Chipscreen Convertible Bonds" Due to Private Placement of Shares
March 3, 2026
Announcement on the Chairman's Proposal to Repurchase Shares
February 27, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Signing Tripartite Supervision Agreement for Deposit of Raised Fund in Special Account
February 25, 2026
Announcement on Execution of a License and Distribution Agreement with Nizhpharm
February 3, 2026
Announcement on the Thawing of Partially Frozen Shares Held by a Shareholder Owning 5% or More of the Company’s Equity
January 30, 2026
Announcement on Proposed Participation of Connected Persons in the Subscription of Shares Issued to Specific Objects and Related Party Transaction
January 29, 2026
Announcement on Earnings Preannouncement for 2025
January 26, 2026
Indicative Announcement on "Chipscreen Convertible Bonds" Expected to Meet Conditions for Redemption
January 22, 2026
Announcement on Estimated Amount of Daily Related Party Transactions in 2026
January 15, 2026
Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)
January 14, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Chiauranib Capsules
January 8, 2026
Announcement on Voluntary Disclosure of Approval of Chidamide for Market Release by the Pharmaceutical Administration Bureau, Macao SAR
January 7, 2026